US 6,150,362 AGranted

Triazine angiogenesis inhibitors

OwnerJack Henkin, Donald J. Davidsoninventors

Life of this patent

Estimating the term…

Abstract

Compounds having Formula I ##STR1## or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting anglogenesis in a mammal.

Claims3

Dependent claims

A method of ameliorating angiogenic diseases comprising administering an effective therapeutic amount of a compound having Formula I, ##STR13## or pharmaceutically acceptable salts or prodrugs thereof, wherein R.sub.1, R.sub.2, R.sub.3, and are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.20 alkyl, and C.sub.1 -C.sub.20 alkanoyl;

or
R.sub.1 and R.sub.2 together with the nitro gen atom to which they are attached form a ring independently selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine;
or
R.sub.3 and R.sub.4 together with the nitrogen atom to which they are attached form a ring independently selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine;
A is selected from the group consisting of heterocycle, (hetero gvcle)--C.sub.1 -C.sub.20 -alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.6 -C .sub.15 spiroalkyl, and --B--L--Y;
B and Y are independently aryl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.10 cycloalkenyl, heterocycle, or C.sub.6 -C.sub.15 spiroalkyl;
L is a covalent bond, --C(.dbd.W)--, C.sub.1 -C.sub.20 alkylene, --NR.sub.5 --, --NR.sub.6 C(X)NR.sub.7 --, C.sub.2 -C.sub.20 alkynylene, C.sub.2 -C.sub.20 alkenylene, --O--, --S(O).sub.t --, --NR.sub.6 C(X)--, --C(X)NR.sub.6, --NR.sub.6 SO.sub.2 NR.sub.7 --, --NR.sub.6 SO.sub.2 --, SO.sub.2 NR.sub.6 --, SO.sub.2 NR.sub.6 --, or --O-- C(R.sub.100)(R.sub.200)--;
R.sub.5 is hydrogen, C.sub.1 -C.sub.20 alkyl, C.sub.1 -C.sub.20 alkanoyl, and C.sub.1 -C.sub.20 arylalkyl;
R.sub.6 and R.sub.7 are independently hydrogen, C.sub.1 -C.sub.20 alkyl, and aryl-C.sub.1 -C.sub.20 -alkyl;
R.sub.100 and R.sub.200 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.20 alkyl, and C.sub.1 -C.sub.20 alkanoyl;
W is O, S, or (.dbd.N--O--R.sub.6) ;
X is O or S;
t is 0-2;
each L is shown with its left end attached to B and its right end attached to Y;
and
at each occurrence, aryl, cycloalkyl, cycloalkenyl, heterocycle, spiroalkyl, alkylene, and (heterocele)alkyl may be optionally substituted with 1-3 substituents independently selected from C.sub.1 -C.sub.20 alkoxy, C.sub.1 -C.sub.20 alkyl, amino, aryl, azido, cyano, halo, C.sub.1 -C.sub.20 haloalkyl, heterocycle, nitro, or ##STR14## wherein A and D are independently oxygen or S(O).sub.t and n is 2-3, with the proviso that when B and Y are unsubstituted phenyl and L is a covalent bond, then at least one of R.sub.1, R.sub.2 ;R.sub.3, and R.sub.4 is other than hydrogen, and
with the proviso that when L is a covalent bond and one of B or Y is unsubstituted imidazole and the other is unsubstituted phenyl, then at least one of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is other than hydrogen.

14 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

or
R.sub.1 and R.sub.2 together with the nitro gen atom to which they are attached form a ring independently selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine;
or
R.sub.3 and R.sub.4 together with the nitrogen atom to which they are attached form a ring independently selected from the group consisting of morpholine, piperidine, piperazine, and pyrrolidine;
A is selected from the group consisting of heterocycle, (hetero gvcle)--C.sub.1 -C.sub.20 -alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.6 -C .sub.15 spiroalkyl, and --B--L--Y;
B and Y are independently aryl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.10 cycloalkenyl, heterocycle, or C.sub.6 -C.sub.15 spiroalkyl;
L is a covalent bond, --C(.dbd.W)--, C.sub.1 -C.sub.20 alkylene, --NR.sub.5 --, --NR.sub.6 C(X)NR.sub.7 --, C.sub.2 -C.sub.20 alkynylene, C.sub.2 -C.sub.20 alkenylene, --O--, --S(O).sub.t --, --NR.sub.6 C(X)--, --C(X)NR.sub.6, --NR.sub.6 SO.sub.2 NR.sub.7 --, --NR.sub.6 SO.sub.2 --, SO.sub.2 NR.sub.6 --, SO.sub.2 NR.sub.6 --, or --O-- C(R.sub.100)(R.sub.200)--;
R.sub.5 is hydrogen, C.sub.1 -C.sub.20 alkyl, C.sub.1 -C.sub.20 alkanoyl, and C.sub.1 -C.sub.20 arylalkyl;
R.sub.6 and R.sub.7 are independently hydrogen, C.sub.1 -C.sub.20 alkyl, and aryl-C.sub.1 -C.sub.20 -alkyl;
R.sub.100 and R.sub.200 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.20 alkyl, and C.sub.1 -C.sub.20 alkanoyl;
W is O, S, or (.dbd.N--O--R.sub.6) ;
X is O or S;
t is 0-2;
each L is shown with its left end attached to B and its right end attached to Y;
and
at each occurrence, aryl, cycloalkyl, cycloalkenyl, heterocycle, spiroalkyl, alkylene, and (heterocele)alkyl may be optionally substituted with 1-3 substituents independently selected from C.sub.1 -C.sub.20 alkoxy, C.sub.1 -C.sub.20 alkyl, amino, aryl, azido, cyano, halo, C.sub.1 -C.sub.20 haloalkyl, heterocycle, nitro, or ##STR14## wherein A and D are independently oxygen or S(O).sub.t and n is 2-3, with the proviso that when B and Y are unsubstituted phenyl and L is a covalent bond, then at least one of R.sub.1, R.sub.2 ;R.sub.3, and R.sub.4 is other than hydrogen, and
with the proviso that when L is a covalent bond and one of B or Y is unsubstituted imidazole and the other is unsubstituted phenyl, then at least one of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is other than hydrogen.

14 more elements